> Investors in Adimab LLC, which makes platform technology for antibody drug discovery, may never see a traditional exit from the company–and they couldn’t be happier about it.

I haven't seen this sort of practice in the software tech scene. Are there any software companies funded in this way, or is it restricted to industries which are traditionally allowed to be slower moving?